Pyxis Oncology (PYXS) Competitors

Kamada has a net margin of 11.21% compared to Pyxis Oncology's net margin of 0.00%. Kamada's return on equity of 7.73% beat Pyxis Oncology's return on equity.

Kamada has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Kamada had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for Kamada and 0 mentions for Pyxis Oncology. Kamada's average media sentiment score of 0.24 beat Pyxis Oncology's score of 0.00 indicating that Kamada is being referred to more favorably in the media.

Kamada presently has a consensus price target of $12.00, indicating a potential upside of 65.75%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 304.34%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Kamada.

Kamada has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

In the previous week, Neurogene had 4 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Neurogene and 0 mentions for Pyxis Oncology. Neurogene's average media sentiment score of 1.19 beat Pyxis Oncology's score of 0.00 indicating that Neurogene is being referred to more favorably in the media.

Neurogene has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neurogene currently has a consensus price target of $73.13, suggesting a potential upside of 155.68%. Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 304.34%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Neurogene.

Neurogene's return on equity of -37.88% beat Pyxis Oncology's return on equity.

Pyxis Oncology has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

In the previous week, Century Therapeutics had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for Century Therapeutics and 0 mentions for Pyxis Oncology. Century Therapeutics' average media sentiment score of 0.00 equaled Pyxis Oncology'saverage media sentiment score.

Century Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Century Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Century Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat Pyxis Oncology's return on equity.

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 124.06%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 304.34%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Century Therapeutics.

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pyxis Oncology has a net margin of 0.00% compared to Canopy Growth's net margin of -94.39%. Canopy Growth's return on equity of -46.85% beat Pyxis Oncology's return on equity.

Canopy Growth has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Canopy Growth had 8 more articles in the media than Pyxis Oncology. MarketBeat recorded 8 mentions for Canopy Growth and 0 mentions for Pyxis Oncology. Canopy Growth's average media sentiment score of 1.09 beat Pyxis Oncology's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Pyxis Oncology has lower revenue, but higher earnings than Canopy Growth. Pyxis Oncology is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Pyxis Oncology has a consensus target price of $6.83, suggesting a potential upside of 304.34%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Canopy Growth.